TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23761964

Group type: EXPERIMENTAL
Intervention: 0.15% GCV in situ ophthalmic gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.15% GCV ophthalmic gel (control)
Number of subjects: 0
Study: 17058824

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SBP) plus routine treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 41
Study: 12938897

Group type: EXPERIMENTAL
Intervention: Experimental group with different instructional communication methods
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group with standard communication methods
Number of subjects: 174
Study: 10804656

Group type: EXPERIMENTAL
Intervention: New methods of diagnostic imaging and staging invasive procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different treatments evaluated in randomized trials
Number of subjects: 0
Study: 8669331

Group type: EXPERIMENTAL
Intervention: Cefminox
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 22
Study: 2107242

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) nebulizer solution 1% administered three to four times daily for 8 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 14
Study: 447899

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Expectation of alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: No expectation of alcohol
Number of subjects: 32
Study: 30854874

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 40
Study: 29773662

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 26661693

Group type: EXPERIMENTAL
Intervention: AD-ON risk score
Number of subjects: 11140
Study: 25711404

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 23294801

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 591

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 591
Study: 19582579

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Open-label lansoprazole therapy (dose-titrated)
Number of subjects: 206
Study: 17884925

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into biceps brachii
Number of subjects: 0
Study: 16463863

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (mild hypothermia group: 32‐34 degrees C, n = 10; very mild hypothermia group: 35‐36 degrees C, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32‐34 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Very mild hypothermia (35‐36 degrees C)
Number of subjects: 20
Study: 12027846

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study: 10323377

Group type: EXPERIMENTAL
Intervention: 4-6 mg/day lacidipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10-20 mg/day lisinopril
Number of subjects: 40
Study: 7795341

Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 180
Study: 1875248

Group type: EXPERIMENTAL
Intervention: Shoulder movement
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Finger opposition
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fist-making
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Index finger movement
Number of subjects: 6
Study: 6271814

Group type: EXPERIMENTAL
Intervention: THC, 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (PCPZ), 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: THC, 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: THC, 15 mg
Number of subjects: 120
Study: 31283756

Group type: EXPERIMENTAL
Intervention: Dofetilide, Moxifloxacin (potassium channel blockers)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mexiletine, Lidocaine (sodium or calcium channel blockers)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ranolazine (multichannel blocking drug)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dofetilide + Mexiletine, Dofetilide + Lidocaine (drug combinations)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tr40c (parameter for differentiating drugs)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: J-Tpeakc (parameter from second FDA study)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of Tr10c to Tr100c in logistic regression model
Number of subjects: 44
Study: 28598453

Group type: EXPERIMENTAL
Intervention: 0.2% Glyceryl Trinitrate (GTN)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% Nifedipine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study: 25646201

Group type: EXPERIMENTAL
Intervention: 20‐mL/kg isotonic saline bolus
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (no fluid bolus)
Number of subjects: 126
Study: 23410851

Group type: EXPERIMENTAL
Intervention: Family economic empowerment intervention (matched children savings accounts, financial management workshops, mentorship)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 297
Study: 21429094

Group type: EXPERIMENTAL
Intervention: Patch users
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Commercially available patches
Number of subjects: 191

Group type: COMPARATOR
Intervention: Non-patch users
Number of subjects: 191
Study: 20110012

Group type: COMPARATOR
Intervention: Once-daily extended-release (ER) pramipexole 0.75 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-dose ER pramipexole 0.375 mg (fasted state)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-dose ER pramipexole 0.375 mg (fed state)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Steady-state ER pramipexole 0.375 to 4.5 mg (fasted state)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Steady-state ER pramipexole 4.5 mg
Number of subjects: 72
Study: 17827952

Group type: EXPERIMENTAL
Intervention: Combination of infliximab with immunosuppressives at onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard approach (step-up strategy)
Number of subjects: 0
Study: 15176536

Group type: EXPERIMENTAL
Intervention: Oral refeeding
Number of subjects: 28

Group type: COMPARATOR
Intervention: Jejunal tube refeeding
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 11814156

Group type: EXPERIMENTAL
Intervention: 10-session group intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 9601682

Group type: EXPERIMENTAL
Intervention: 5‐HT2A receptor promoter polymorphism ‐1438G/A in patients with mood disorders
Number of subjects: 95

Group type: COMPARATOR
Intervention: Healthy Japanese controls
Number of subjects: 95
Study: 8017593

Group type: EXPERIMENTAL
Intervention: 0.1% pethidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2% pethidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% prilocaine
Number of subjects: 0
Study: 2684554

Group type: EXPERIMENTAL
Intervention: CPAP treatment after 1 night
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CPAP treatment after 14 nights
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CPAP treatment after 42 nights
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 39
Study: 1102646

Group type: EXPERIMENTAL
Intervention: Antiheart antibody (AHA) in high titer
Number of subjects: 257

Group type: COMPARATOR
Intervention: No AHA
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Rise in titer to viral agents
Number of subjects: 257
Study: 30987619

Group type: EXPERIMENTAL
Intervention: Functional metacarpal splint (FMS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ulnar gutter splint (UGS)
Number of subjects: 58
Study: 28274253

Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Namilumab 300 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Namilumab (150 and 300 mg combined)
Number of subjects: 24
Study: 25567115

Group type: EXPERIMENTAL
Intervention: Anrukinzumab 200 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Anrukinzumab 400 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Anrukinzumab 600 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Anrukinzumab (all doses)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Anrukinzumab and Placebo
Number of subjects: 84
Study: 23787775

Group type: EXPERIMENTAL
Intervention: Genuine UMTS RF EMF exposure (1.75 W/kg for 30 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham condition (placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 21710265

Group type: EXPERIMENTAL
Intervention: 80 kV
Number of subjects: 42

Group type: COMPARATOR
Intervention: 120 kV
Number of subjects: 42
Study: 18059046

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0
Study: 16469404

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone 30 mg daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Antioxidant cocktail
Number of subjects: 101
Study: 14506496

Group type: EXPERIMENTAL
Intervention: 2 g/day of fish oil (containing approximately 450 mg eicosapentaenoic acid and 350 mg docosahexaenoic acid)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 10684911

Group type: EXPERIMENTAL
Intervention: Metronidazole (two 2-g doses)
Number of subjects: 1953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1953
Study: 8823580

Group type: EXPERIMENTAL
Intervention: Lodoxamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study: 1481177

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 2 1/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4 1/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 6 1/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline unburdened walk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Portable gas supply
Number of subjects: 30
Study: 3970608

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electrolyte cardioplegia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 20
Study: 29419785

Group type: EXPERIMENTAL
Intervention: Liquid nutritional formula
Number of subjects: 14

Group type: COMPARATOR
Intervention: Solid breakfast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liquid product
Number of subjects: 14
Study: 26733410

Group type: EXPERIMENTAL
Intervention: SkQ1 1.55 µg/mL
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SkQ1 0.155 µg/mL
Number of subjects: 91

Group type: COMPARATOR
Intervention: 0.0 µg/mL (placebo)
Number of subjects: 91
Study: 24378998

Group type: EXPERIMENTAL
Intervention: Barostim therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 1
Study: 22503105

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) therapy with prednisone, initiated at 0.05 mg/kg/d, adjusted to maintain a trough blood level of 5 to 10 ng/mL for 1 year.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous (IV) pulse cyclophosphamide (CTX) therapy with prednisone, initiated at 1 g/1.73 m(2) for a total dosage of 10 g/1.73 m(2) over 1 year.
Number of subjects: 37
Study: 20489031

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus pravastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus rosuvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalcetrapib alone and coadministered with statins
Number of subjects: 0
Study: 18064444

Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cotinine/Nicotine
Number of subjects: 12
Study: 16126119

Group type: EXPERIMENTAL
Intervention: metformin+RSG 4 mg b.i.d.
Number of subjects: 38

Group type: COMPARATOR
Intervention: metformin+placebo
Number of subjects: 38
Study: 12198218

Group type: EXPERIMENTAL
Intervention: CAHP‐210 hemodialyzer with vancomycin infused during the last hour of dialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Post-haemodialysis administration of vancomycin 15 mg/kg
Number of subjects: 8
Study: 9445320

Group type: EXPERIMENTAL
Intervention: rpro-UK (6 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7621133

Group type: EXPERIMENTAL
Intervention: 12% O2 in N2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 16% O2 in N2
Number of subjects: 5

Group type: COMPARATOR
Intervention: 21% O2 in N2 (normoxia)
Number of subjects: 5
Study: 2495144

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 1 hour exposure time
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mitomycin-C (MMC) 0.5 hour exposure time
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Number of subjects: 70
Study: 327955

Group type: EXPERIMENTAL
Intervention: Seventh-Day Adventists (strict vegetarians)
Number of subjects: 28

Group type: COMPARATOR
Intervention: General western diet
Number of subjects: 28
Study: 6789350

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg orally)
Number of subjects: 0
Study: 31881992

Group type: EXPERIMENTAL
Intervention: Bladder stimulation
Number of subjects: 770

Group type: COMPARATOR
Intervention: Urinary catheterization
Number of subjects: 770
Study: 29985014

Group type: EXPERIMENTAL
Intervention: Vocational Empowerment Photovoice (VEP) program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 51
Study: 26918564

Group type: EXPERIMENTAL
Intervention: 28-day buprenorphine taper
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 56-day buprenorphine taper
Number of subjects: 53
Study: 25086842

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2774

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2774
Study: 23421088

Group type: EXPERIMENTAL
Intervention: Emdogain treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (regular open flap procedure)
Number of subjects: 28
Study: 22958267

Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17991267

Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 38

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 38
Study: 15640389

Group type: EXPERIMENTAL
Intervention: REX-albuterol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: REX-placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unloaded controls
Number of subjects: 0
Study: 11988606

Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 13
Study: 9826114

Group type: COMPARATOR
Intervention: (+)-UH232, single doses of 80 to 180 mg
Number of subjects: 6
Study: 7662761

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 35
Study: 2674821

Group type: EXPERIMENTAL
Intervention: Bendazac lysine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 71969

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg to 200 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin (75 mg to 100 mg daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 26
Study: 30053042

Group type: EXPERIMENTAL
Intervention: 50 mg of AL-794
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 150 mg of AL-794
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 28684232

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) with shoulder extension and internal rotation for 20 to 120 seconds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) for 10 seconds
Number of subjects: 20
Study: 25999434

Group type: EXPERIMENTAL
Intervention: (68)Ga-DOTA-exendin-4 PET/CT
Number of subjects: 5

Group type: COMPARATOR
Intervention: (111)In-DOTA-exendin-4 SPECT/CT
Number of subjects: 5
Study: 23666599

Group type: EXPERIMENTAL
Intervention: RAHelp online intervention with weekly telephone support
Number of subjects: 106

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 106
Study: 21858614

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.75% ropivacaine (Group 5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10 mL of 0.75% ropivacaine (Group 10)
Number of subjects: 60
Study: 19726188

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) as a countermeasure during 8 weeks of bed rest
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no exercise) during 8 weeks of bed rest
Number of subjects: 12
Study: 17302069

Group type: EXPERIMENTAL
Intervention: Refined Xuefu Capsule (RXC) for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (Warfarin only)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Refined Xuefu Capsule (RXC)
Number of subjects: 38
Study: 15472166

Group type: EXPERIMENTAL
Intervention: Metformin administration (850 mg twice daily for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD) with multivitamins
Number of subjects: 120
Study: 10845352

Group type: EXPERIMENTAL
Intervention: Active Music Therapy (MT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 32
Study: 9105740

Group type: EXPERIMENTAL
Intervention: Endoventricular streptokinase infusion (20,000 U/day for 96 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not treated with streptokinase)
Number of subjects: 12
Study: 8472407

Group type: EXPERIMENTAL
Intervention: Cementless THA
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cemented THA
Number of subjects: 127
Study: 3102167

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied 3-times daily for 4 to 10 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Erythromycin (oral) in normal dosage for skin infections
Number of subjects: 200

Group type: COMPARATOR
Intervention: Flucloxacillin (oral) in normal dosage for skin infections
Number of subjects: 200
Study: 31021033

Group type: EXPERIMENTAL
Intervention: Pontine infarction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Striato-capsular infarction
Number of subjects: 40
Study: 29029237

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 220

Group type: COMPARATOR
Intervention: No-CPAP
Number of subjects: 220
Study: 25956171

Group type: EXPERIMENTAL
Intervention: Five-drug ART (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Three-drug ART (tenofovir+emtricitabine+efavirenz, n=18)
Number of subjects: 54
Study: 23873255

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 21375852

Group type: EXPERIMENTAL
Intervention: Hyaluronate-iodine soaked gauze applied to wounds either daily or every other day depending on the amount of wound exudate.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hyaluronate-iodine
Number of subjects: 14
Study: 18650064

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Percentage global scar area (GSA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: GSA </= 18%
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: End-diastolic wall thickness (EDWT) < 6 mm
Number of subjects: 74
Study: 17302372

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) at a dosage of 1 mg/kg body weight, administered orally to CCoV-infected dogs.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study: 12890273

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy treatment for 12 weeks
Number of subjects: 135
Study: 10098804

Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 33
Study: 8550780

Group type: EXPERIMENTAL
Intervention: 1.25 mg esterified estrogen and 2.5 mg methyltestosterone (E+A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 1.25 mg conjugated equine estrogen (CEE)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both regimens (E+A and CEE)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: E+A
Number of subjects: 2
Study: 1909978

Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate 600 microgram/d plus hMG
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate 1,200 microgram/d plus hMG
Number of subjects: 157

Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate
Number of subjects: 157
Study: 6619040

Group type: EXPERIMENTAL
Intervention: ticarcillin (4.0 g every 6 h for 7 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: mezlocillin (4.0 g every 6 h for 7 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo (4.0 g every 6 h for 7 days)
Number of subjects: 18